Thursday - December 25, 2025
FDA Proactively Awards National Priority Voucher Based on Strong Phase 3 Study Results
December 15, 2025
WASHINGTON, Dec. 15 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following news release:

* * *

FDA Proactively Awards National Priority Voucher Based on Strong Phase 3 Study Results

*

The U.S. Food and Drug Administration today awarded a national priority voucher to teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma. This brings the total number of products receivi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products